ED drugs and risk for prostate cancer recurrence? … NOT!

Back in February 2015 a group of German researchers published a study suggesting that there was a small but significantly increased risk of biochemical recurrence after prostate cancer treatment among men using drugs like sildenafil (Viagra) to recover/stimulate erectile function. … READ MORE …

What to do with a man with M0 or M1 disease who is progressing on treatment

Is the addition of enzalutamide (Xtandi) to an LHRH agonist now the appropriate standard of care for a man with M0 or M1 prostate cancer who starts to progress on treatment with an LHRH agonist alone? … READ MORE …

SBRT registries (and the interpretation of registry-based data)

Patient registries are potentially a rich source of information with which to evaluate outcomes. They often include patient characteristics, details of the therapies they received, and outcomes tracked over time. They also provide full population data of all patients treated at participating centers, and can provide very large amounts of data over time. … READ MORE …

St. Gallen consensus conference on treatment of advanced prostate cancer

Apparently, early in 2015, there was a major international consensus conference, among nearly 50 of the leading international authorities, on the treatment of advanced prostate cancer. … READ MORE …

The FDA’s perspective on the approval of HIFU in the USA

For those able to access the February 2016 issue of the AUA News, it carries an interesting article outlining the U.S. Food and Drug Administration’s perspective on exactly why the agency decided to approve two forms of high-intensity focused ultrasound (HIFU) technology for the transrectal ablation of prostate tissue. … READ MORE …

Publication of final data from the TRAPEZE trial

Some 2½ years ago, James presented data from the TRAPEZE trial at the annual meeting of the American Society of Clinical Oncology in Chicago. At the time, we described these data as “unsurprising.” … READ MORE …

Risk for infection(s) from fiducial marker placement

Most of us who have gone through any form of image-guided external beam radiotherapy have had TRUS-guided transrectal placement of gold fiducial markers or radio transponders placed in our prostates. Some who have had salvage radiation have had them placed in the prostate bed. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,367 other followers